Because of the relevance of HbA1c in disease outcomes related to diabetes, such as neuropathy [20], nephropathy [21], and especially cardiovascular disease [22], numerous conventional clinical interventions seek to lower glucose and HbA1c by increasing insulin via either insulin therapy or insulin secretagogues, such as sulfonylureas. Here, INS is linked to neuropathy.